The latest news and announcements from Emory University and Emory Healthcare about coronavirus.
12/23/21:Molnupiravir, an investigational oral antiviral drug invented by scientists at Emory University, has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19.
Media Contacts
Janet Christenbury
404-727-8599
jmchris@emory.edu
Gana Ahn
404-727-0343
gana.ahn@emory.edu
On Dec. 23, molnupiravir, an investigational oral antiviral drug invented by scientists at Emory University, received Emergency Use Authorization from the FDA for the treatment of COVID-19.
Emory has a number of faculty members and health care professionals who can speak about many facets of the COVID-19 outbreak.
Molnupiravir, an investigational oral antiviral drug discovered by Emory researchers, appears to significantly reduce the risk of hospitalization or death in patients with mild to moderate COVID-19, according to interim data from a Phase 3 study.
Emory pulmonologist Alex Truong joins epidemiologist Jodie Guest to answer questions about long COVID, including who is at risk and what symptoms people may experience.
The U.S. Food and Drug Administration (FDA) has approved Pfizer-BioNTech’s COVID-19 vaccine. Emory experts are available to discuss the FDA approval announcement as well as all the other ways COVID-19 continues to impact us all.
In a conversation recorded Aug. 24, 2021, Emory infectious disease experts Aneesh Mehta and Colleen Kelley answer questions about FDA approval COVID-19 vaccines, virus variants, masking and more.
Emory researchers have been involved in testing all three of the COVID-19 vaccines currently in use in the United States, along with others that may play important roles in the future.
Recovered COVID-19 patients retain broad and effective longer-term immunity to the disease, suggests a recent Emory University study, which is the most comprehensive of its kind so far. The findings have implications for expanding understanding about human immune memory as well as future vaccine development for coronaviruses.
To address the intensifying COVID-19 crisis in India, the pharmaceutical company Merck has agreed to facilitate the manufacture and distribution of molnupiravir, an investigational antiviral drug that was discovered at Emory.
A more contagious coronavirus variant known as B.1.1.7 is still susceptible to antibodies induced after COVID-19 infection or vaccination. But another called B.1.351 modestly reduces antibodies' potency.
Emory University researchers have enhanced their dynamic national COVID-19 Health Equity Dashboard to provide more localized information on the impact of the pandemic in communities across Georgia.
An antiviral drug initially discovered by Emory’s non-profit drug development company DRIVE appears safe and reduces SARS-CoV-2 to undetectable levels in COVID-19 patients after five days of administration, according to data from a Phase II clinical trial.
